以卡瑞利珠单抗为基础的联合治疗策略治疗晚期食管鳞状细胞癌的临床疗效

Clinical efficacy of camrelizumab-based combination therapy strategy in the treatment of advanced esophageal squamous cell carcinoma

目的探讨以卡瑞利珠单抗为基础的联合治疗策略治疗晚期食管鳞状细胞癌的临床疗效。方法将48例晚期/转移性食管鳞状细胞癌患者按治疗方法的不同分为对照组12例和观察组36例。对照组患者给予卡瑞利珠单抗治疗,观察组患者给予卡瑞利珠单抗联合化疗或靶向治疗,其中卡瑞利珠单抗联合化疗29例,卡瑞利珠单抗联合阿帕替尼治疗7例。比较两组患者的临床疗效、生存情况和不良反应发生情况。结果观察组患者疾病控制率(DCR)为72.22%(26/36),高于对照组的33.33%(4/12),差异有统计学意义(P﹤0.05)。观察组患者中位无进展生存期(PFS)、总生存期(OS)均长于对照组,差异均有统计学意义(P﹤0.05)。两组患者各不良反应发生率比较,差异均无统计学意义(P﹥0.05)。结论卡瑞利珠单抗联合化疗或靶向治疗能改善晚期食管鳞状细胞癌患者的PFS和OS,且耐受性较好。

Objective To investigate the clinical efficacy of camrelizumab-based combination therapy strategy in the treatment of advanced esophageal squamous cell carcinoma.Method A total of 48 patients with advanced/metastatic esophageal squamous cell carcinoma were divided into the control group(n=12)and the observation group(n=36)according to different treatment methods.The patients in the control group were treated with camrelizumab,and the patients in the observation group were treated with camrelizumab combined with chemotherapy or targeted therapy,including 29 cases of camrelizumab combined with chemotherapy and 7 cases of camrelizumab combined with apatinib.The clinical efficacy,incidence of survival and adverse reactions of the two groups were compared.Result The disease control rate(DCR)in the observation group was 72.22%(26/36),which was higher than 33.33%(4/12)in the control group,the difference was statistically significant(P<0.05).The median progression-free survival(PFS)and overall survival(OS)of the observation group were longer than those of the control group,the differences were statistically significant(P<0.05).There were no significant differences in the incidence of adverse reactions between the two groups(P>0.05).Conclusion Camrelizumab combined with chemotherapy or targeted therapy can improve the PFS and OS of patients with advanced esophageal squamous cell carcinoma,and it is well tolerated.